protein tyrosine kinase 7 (inactive)Genealiases: CCK-4 · CCK4
Q-omics provides the consensus-scored PTK7 profile across patient tissues and cancer cell-line models. PTK7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PTK7 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PTK7 protein abundance shows 22,296 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, HNSC, and UCEC as cancer lineages where PTK7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTK7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTK7 survival associations across molecular data types. PTK7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTK7 RNA expression–survival associations across cancer types. High PTK7 expression shows unfavorable associations in MESO, ACC, LGG and CESC, but favorable associations in LUAD and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for PTK7 RNA expression.
This table summarizes PTK7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PTK7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTK7 shows lower tumor expression in KIRC and higher tumor expression in HNSC, COAD, BLCA, LIHC and BRCA. The HNSC box plot shows higher PTK7 RNA expression in tumor versus normal tissue (log2 FC = +2.305, t-test p < 0.001).
This table shows molecular features associated with PTK7 in patient tissues and cancer cell lines. In patient samples, PTK7 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTK7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
